close

News

LATEST POSTS from News

New solution for stem cell manufacturing

New solution for stem cell manufacturing Researchers have developed a unique 3D printed system for harvesting stem cells from bioreactors, offering the potential for high quality, wide-scale production of stem cells in Australia at a lower cost. [caption id="attachment_10614" align="aligncenter" width="700"] Modular 3D printed microfluidic system©Majid Warkiani et al. Bioresources…..

Coriolis Pharma creates a new campus in Martinsried-Munich

Coriolis Pharma creates a new campus in Martinsried-Munich Coriolis Pharma, a globally operating contract research and development organization (CRDO) and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, ATMP´s and vaccines, is expanding its current headquarters to form a new campus as the next step…..

TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies

TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies TreeFrog Therapeutics, a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), announced the incorporation of its Japanese subsidiary…..

Novasep and PharmaZell become one group

Novasep, a major CDMO focused on complex small molecules and antibody-drug conjugates (ADCs), and PharmaZell, a leading supplier of highly resilient and specialty APIs, have just closed their merger, following exclusive negotiations initiated in September 2021. This strategic merger creates a technology driven, leading Franco-German CDMO and API manufacturer. Novasep’s…..

Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility

Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility   The FDA has granted commercial licensure approval for Novartis' Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma®, as well as produce…..

On World Bipolar Day ALCEDIAG announces EIT Health supported EDIT-B Consortium validating innovative blood diagnostic test for bipolar disorder

On World Bipolar Day ALCEDIAG announces EIT Health supported EDIT-B Consortium validating innovative blood diagnostic test for bipolar disorder   ALCEDIAG announced the launch of the EDIT-B Consortium, supported by the European Institute of Innovation and Technology for Health (EIT Health). This newly formed European public-private partnership aims at advancing…..